As dosing intervals of TLR7 agonists have been reported to be an important factor for immunostimulatory activity [23], we compared the effect of once weekly (q1w) DSP-0509 dosing frequency with that of biweekly (q2w) on the anti-tumor activity of the RT and DSP-0509 combination (Fig. 2A). Here, TLR7 is linked to neoplasm.